<DOC>
	<DOCNO>NCT02211833</DOCNO>
	<brief_summary>Exploratory evaluation safety , tolerability , pharmacokinetics ( PK ) , maximum tolerate dose ( MTD ) , efficacy BI 2536 administer combination pemetrexed</brief_summary>
	<brief_title>Dose Escalation Study BI 2536 With Pemetrexed Previously Treated Patients With Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Pathologic cytologic confirm diagnosis NSCLC 2 . Recurrent , advance metastatic NSCLC progress follow 1 prior chemotherapy regimen advance disease . Patients could receive prior adjuvant chemotherapy long disease free interval longer 1 year . 3 . Measurable disease 1 technique ( CT , MRI ) accord RECIST criterion 4 . Male female age 18 year old 5 . Life expectancy least 3 month 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 7 . Written inform consent consistent International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) guideline 1 . Treatment investigational drug another clinical study within 28 day prior start therapy concomitantly study 2 . Anticancer therapy NSCLC ( except radiotherapy palliative reason ) within 28 day prior Day 1 treatment period 1 trial 3 . Any persist toxicity deem clinically significant previous therapy 4 . Received 1 prior chemotherapy regimen advance disease ( include prior adjuvant therapy ) . Patients could receive prior epidermal growth factor receptor tyrosine kinase inhibitor 5 . Unwilling unable take folic acid vitamin B12 supplementation 6 . Active brain metastasis ( stable &lt; 28 day , symptomatic , require concurrent steroid ) . Patients receive prior whole brain irradiation whose brain metastases stable accord criterion exclude 7 . Other active malignancy diagnose within past 3 year ( nonmelanomatous skin cancer cervical intraepithelial neoplasia ) 8 . Concomitant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit compliance trial requirement consider relevant evaluation efficacy safety trial drug 9 . Unable unwilling interrupt concomitant administration NSAIDS 5 day prior day 2 day administration pemetrexed 10 . Received prior therapy pemetrexed 11 . Absolute neutrophil count ( ANC ) ≤1 500/μL , platelet count ≤100 000/μL , haemoglobin &lt; 9 mg/dL 12 . Total bilirubin &gt; 1.5 mg/dL ( 26 μmol/L ) , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≥2.5 x upper limit normal ( ULN ) , except case know liver metastasis maximum 5 x ULN acceptable 13 . Serum creatinine level &gt; 1.5 mg/dL creatinine clearance &lt; 45 mL/min 14 . Sexually active unwilling use medically acceptable method contraception 15 . Pregnancy breast feed 16 . Known suspect active alcohol drug abuse 17 . Unable comply protocol 18 . Any known hypersensitivity trial drug excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>